Immobilized Human PCSK9, His Tag at 2 μg/ml (100 μl/Well) on the plate. Dose response curve for Anti-PCSK9 antibody, hFc Tag with the EC50 of 0.13 μg/ml determined by ELISA (QC Test).
Human LDLR, His Tag immobilized on CM5 Chip can bind Human PCSK9, His Tag with an affinity constant of 0.35 nM as determined in SPR assay (Biacore T200).

Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER , the pro domain and mature chain secrete together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.

> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC